The many surprising uses of Pfizer's newest acquisition: Botox
Reuters/ Jim Young
The $160 billion deal is the year's largest takeover.
One of the reasons Allergan is worth so much is Botox, which had more than $2 billion in annual sales in 2013.
One of the most common pharmaceutical products, Botox is currently known as an anti-wrinkle treatment. However, the drug has many other approved medical uses...
View As: One Page Slides
Meet the bacterial neurotoxin that went on to be a medicine.
While studying food poisoning in the 1800s, German physician Justinus Kerner realized that there were neurological components to the Clostridium botulinum bacteria which causes botulism, an extreme form of food poisoning that causes difficulty swallowing, muscle weakness, paralysis, and even death if left untreated.
From there, Kerner went on to see if there were any therapeutic effects to the neurotoxins that the bacteria gave off.
Botox's most famous use — treating wrinkles — started as an "off-label" use in the 1990s, but was officially approved by the FDA in 2002.
During the 1990s, while researchers were exploring all the different ways to use Botox, doctors began to use the drug "off-label" (meaning the FDA has yet to approve it) to smooth out wrinkles temporarily. Botox became so popular that at one point in 1997, the US ran out of its supply, inciting a panic for those using it for off-label wrinkle removal.
Allergan officially got FDA approval for cosmetic Botox to treat glabellar lines (the wrinkles between your eyebrows also known as frown lines) in 2002.
But Botox was actually first used to treat crossed eyes.
For many years after Kerner's research, botulinum toxin was avoided, in part because there were fears about it getting into the wrong hands and being used as a deadly weapon.
But in 1980, ophthamologist Alan B. Scott started looking into botulinum toxin Type A as a way to treat strabismus, or crossed eyes. By 1987, eye doctors used the neurotoxin to correct these crossed eyes with pretty good results.
Next, eye doctors tried it to treat a condition that causes abnormal blinking.
Also in the 1980s, eye doctors looked into botulinum toxin's use in another eye condition: blepharospasm, which causes abnormal blinking and tightening of eyes. While treating the eye disorder, the researchers also noticed that wrinkles began to disappear around the injection sites near the eyes. Allergan acquired the rights to botulinum toxin from Scott in 1988, putting it on track for FDA approval and giving it the marketing name Botox.
Botulinum toxin was approved by the FDA to treat strabismus and blepharospasm in 1989.
Next up: A condition that causes people to turn their heads to the side involuntarily.
After its original approvals for those eye conditions, Allergan began to explore what other areas they could treat. By 2000, they had won approval from the FDA to use Botox to treat cervical dystonia, a condition in which the muscles of the neck cause the head to turn a certain way.
It also treats extreme underarm sweating.
While experimenting, researchers began to figure out that Botox could be used on other areas of the body, especially areas in danger of extreme sweating.
In 2004, the FDA approved Botox injections for severe axillary hyperhidrosis, otherwise known as severe underarm sweating, that can't be treated with topical treatments. The Botox works by confusing the nerve endings in the armpit, which keeps the sweat glands from feeling the need to produce sweat.
And some people use it to stop sweating in other areas, like the scalp.
To be clear: Botox is only approved to treat underarm sweat and doesn't necessarily work on any other areas. But because it's so successful in treating underarm sweating, some women are getting the injections under their hair to keep it from getting too sweaty and frizzy after a particularly strenuous workout. According to FastCompany, it's common for SoulCycle fanatics.
More recently, it's been used to treat muscle spasms in the upper arm.
The 2010s have been a good time for Allergan and Botox. The company had already won a number of approvals, and to kick off the decade the company got approval to treat two more medical conditions with Botox. The first was for upper limb spasticity, a condition that affects how you move your arms and causing spasms in those muscles.
It works on chronic migraines.
Later that year, the FDA approved using Botox to treat chronic migraines, which is defined as having a headache for most days of the month. Migraines can be debilitating pain, often accompanied by other unpleasant symptoms like nausea and sensitivity to light and sound. An injection once every three months can paralyze some of the nerves in the head connected to these migraines.
It can be injected into the bladder muscle to stop incontinence.
Since then, the drug proved an effective way to deal with bladder conditions, such as overactive bladder and urinary incontinence, or the involuntary leakage of urine. Botox proved effective, when injected into the bladder muscle, at helping the bladder relax and keeping it from overacting and leaking.
And it's the only approved treatment for crows' feet.
Allergan got its second cosmetic Botox approval in 2013 for use on lateral canthal lines, also known as crows; feet. It's so far the only approved treatment for this kind of wrinkles.
There could be more on the way, including cerebral palsy and heart conditions.
According to Allergan after its recent R&D day, the company has a total of 18 more possible uses for Botox, of which six are already under consideration by the FDA. Some are for therapeutic areas like juvenile cerebral palsy, heart conditions, along with more cosmetic areas.
Next Story
Income tax cuts and new tax slabs — here’s how Indian Finance Minister Nirmala Sitharaman wants to make people shop more- The dean of IIT Roorkee says what you learn in graduation will be obsolete in 3 years
- Toons tell the top stories of 2019 — with a dash of sarcasm
- Indian techies looking to change jobs in 2020 — business is getting tighter for the likes of Infosys, TCS, HCL Tech and their peers
- Your ‘healthy’ diet is making the Indian economy leaner — but it’s not for you to change
- More bad newzz for Salman Khan as Akshay’s movie cuts into his Dabangg earnings
- Cyrus Mistry was proven right on at least four of his warnings to the Tata Sons Board even before the latest court ruling
- A common mistake mutual fund investors make can be fixed through five simple steps
SIGN IN WITH
FacebookGoogleEmail